Last reviewed · How we verify
Alemtuzumab plus Fludarabine
Alemtuzumab is a monoclonal antibody targeting CD52, a protein found on the surface of mature lymphocytes. Fludarabine is a purine analog that inhibits DNA synthesis.
Alemtuzumab is a monoclonal antibody targeting CD52, a protein found on the surface of mature lymphocytes. Fludarabine is a purine analog that inhibits DNA synthesis. Used for Chronic lymphocytic leukemia.
At a glance
| Generic name | Alemtuzumab plus Fludarabine |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Drug class | Monoclonal antibody and purine analog |
| Target | CD52 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Alemtuzumab works by depleting lymphocytes, while fludarabine inhibits the proliferation of cancer cells.
Approved indications
- Chronic lymphocytic leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Infections
Key clinical trials
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (PHASE1, PHASE2)
- Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (PHASE1)
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas (PHASE1)
- Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alemtuzumab plus Fludarabine CI brief — competitive landscape report
- Alemtuzumab plus Fludarabine updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI